The potential for ligands based on the GHRP-6 structure to target ischemic cardiomyopathy was however limited due to their lack of receptor selectivity, binding to both CD36 and the growth hormone secretagogue receptor (so-called ghrelin receptor, GHS-R1a). This evidence concerns the gene GHSR and ischemic cardiomyopathy.